Civil money penalties
This article was originally published in The Gray Sheet
FDA is extending to Aug. 25 the comment period on its proposed rule "to establish hearing procedures when a hearing is requested concerning" the imposition of civil money penalties for medical devices, drugs and biologics, according to a July 27 Federal Register announcement.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.